The Supply Agreement Clause Nobody Negotiates: What Happens When the Patent Gets Invalidated Early
In fiscal year 2021, 167 of the 199 patent settlements pharmaceutical companies filed with the Federal Trade Commission contained a
If Your Patent Database Can’t Answer ‘What Can We Do With This?’ It Isn’t Strategic Intelligence
On June 4, 2026, the Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not induce patent infringement by selling a
Your Formulary Committee Is Budgeting Around a Patent Date That’s Already Been Extended Twice
Enbrel’s first composition patent expired in 2010. The drug is still exclusive in the United States sixteen years later, and
Why Wholesalers Who Overstock Branded Drugs Are Betting Against a Patent Docket They Never Checked
Right now, a patent-tracking service will tell you that Eliquis’s original composition-of-matter patent, U.S. Patent 6,967,208, is set to expire
The Specialty Pharmacy Margin Everyone Protects Disappears the Day a Generic Launches
Generic imatinib entered the US market on February 1, 2016, at 96 percent of the price of branded Gleevec. Sun
The Specialty Pharmacy Margin Everyone Protects Disappears the Day a Generic Launches Read Post »
The State Drug Affordability Board Is Watching Patent Listings You Haven’t Checked in a Year
On July 1, 2026, a federal judge in Denver blocked Colorado’s price cap on Enbrel. The board that set the
The Forum You File In Changes Your Odds More Than the Merits Do
In 2015, a Delaware federal judge looked at prior art covering an antioxidant added to a rivastigmine skin patch and
The Forum You File In Changes Your Odds More Than the Merits Do Read Post »
Why Your PBM’s Generic Substitution Policy Is Six Months Behind the Actual Patent Timeline
The Short Answer Six months is the optimistic case. When Amgen launched the first Humira biosimilar on January 31, 2023,
The Territoriality Trap: Why a US Patent Win Means Nothing Where the Molecule Was Never Filed
On October 2, 2023, the Patent Trial and Appeal Board refused to institute Mylan’s inter partes review of two Novo
